ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 132

Novel Therapeutic Peptides Which Target CD206 Inhibit Macrophage Dependent Fibroblast Activation in Scleroderma

Bahja Ahmed Abdi1, Henry Lopez2, George Martin3, Charles Garvin3, Jesse Jaynes3, James Stanway4, Christopher P. Denton5, David Abraham6, Shivanee Vigneswaran7, Sian Morris7 and Richard J Stratton8, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Murigenics, Vallejo, CA, 3Riptide Bioscience, Vallejo, CA, 4Centre for Rheumatology and Connective Tissue diseases, University College London, London, United Kingdom, 5UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 6Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 7Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 8Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Macrophage, scleroderma and therapeutic targeting

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Alternatively activated macrophages expressing CD206 are believed to promote fibrosis in a range of disorders including systemic sclerosis (SSc). Novel therapeutic peptides (RP) which enter the cell by binding CD206 may selectively inhibit this population of cells. We investigated the potential for RP peptides to suppress fibrosis in experimental mice and in model systems using SSc derived macrophages. sCD206 and CD206 cell surface expression were evaluated as biomarkers in SSc.

Methods: RP therapeutic peptides 10mg/kg were administered by twice daily subcutaneous injection during dermal and lung bleomycin fibrosis models, in wild type C57BL/6 female mice (n=10 mice per group). SSc macrophage viability was assayed by Presto Blue assay. SSc macrophage-fibroblast cross-talk was modelled using transfer of media followed by qPCR for collagen I. sCD206 was assayed by ELISA in plasma (n=40 healthy control (HC) and 40 diffuse SSc) and blister fluid (BF) (n=12 HC and 13 SSc). SSc monocyte-derived macrophages (n=17 SSc & 9 HC) were profiled by flow cytometry for CD206 (M2) and P2X7 (ATP receptor) expression, and by qPCR for arginase (M2) and IFNg (M1).

Results: In mouse models, RP peptides inhibited both the dermal and lung fibrosis induced by bleomycin, and reduced plasma cytokines to basal levels (skin model; dermal thickness in controls 343, bleo 402, bleo +RP 345 um, p<0.0009, plasma IL-6 in bleo 101 pg/ml, bleo+RP 24, p<0.00018, plasma IL12p40 bleo 38, bleo+RP 0, p<01.5×10-7) (lung model; Ashcroft score bleomycin 5.8, bleo+RP 2.8, p<0.0024, plasma IL6 bleo 58, bleo+RP 7 p<0.0005, IL12p40 bleo 152, bleo+RP0, p<0.00014).

As a biomarker, sCD206 was elevated in SSc plasma (SSc median 683, HC 583 pg/ml, p<0.024), and BF (SSc median sCD206 42, HC 31 pg/ml, p<0.041). Both CD206 and P2X7 were highly expressed by SSc macrophages (mean fluorescence SSc, 776.1 SD=409.1, 724.4 SD=455.3 vs HC 632.2 SD=73.7, 472.9 SD=25.4), correlating with modified Rodnan skin score (p<0.05, r=0.51). Double positive P2X7 and CD206 cells were seen in a subgroup with higher skin scores. SSc macrophages had elevated arginase:IFNg ratio (11.4 vs 5.9, p=0.03 ).

RP therapeutic peptides suppressed viability in SSc macrophage cultures with raised arginase:IFNγ ratio >8, but had no effect on macrophages with lower arginase:IFNγ. Treatment of SSc macrophages with RP832c, as the lead candidate, effectively abolished macrophage-fibroblast cross-talk, reducing collagen I to basal levels (collagen I, basal 2830, TGFbeta stimulated 3026, SSc macrophage media treated 4186, RP832c 10µM macrophage media 3519, RP832c 100uM macrophage media 2475, relative expression to TBP, p<0.0039).

Conclusion: These data confirm the presence of activated CD206 positive macrophages in SSc, and demonstrate the potential for these cells to directly stimulate fibroblasts, inducing collagen I. Furthermore, the RP peptides suppress fibrosis and cytokines in mouse models and selectively inhibit highly activated SSc macrophages. RP832c, the lead compound, blocked SSc macrophage-fibroblast cross-talk and will be developed as a GLP therapeutic for clinical trials.


Disclosure: B. Ahmed Abdi, None; H. Lopez, Riptide Bioscience, 4; G. Martin, Riptide Bioscience, 4; C. Garvin, Riptide Bioscience, 4; J. Jaynes, Riptide Bioscience, 4; J. Stanway, None; C. P. Denton, Roche, Actelion, GlaxoSmithKline, Sanofi-Aventis, Inventiva, SCL Behring, Boehringer-Ingelheim, Bayer., 5; D. Abraham, None; S. Vigneswaran, None; S. Morris, None; R. J. Stratton, None.

To cite this abstract in AMA style:

Ahmed Abdi B, Lopez H, Martin G, Garvin C, Jaynes J, Stanway J, Denton CP, Abraham D, Vigneswaran S, Morris S, Stratton RJ. Novel Therapeutic Peptides Which Target CD206 Inhibit Macrophage Dependent Fibroblast Activation in Scleroderma [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/novel-therapeutic-peptides-which-target-cd206-inhibit-macrophage-dependent-fibroblast-activation-in-scleroderma/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-therapeutic-peptides-which-target-cd206-inhibit-macrophage-dependent-fibroblast-activation-in-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology